JP2020518584A - 細胞傷害誘導治療剤 - Google Patents

細胞傷害誘導治療剤 Download PDF

Info

Publication number
JP2020518584A
JP2020518584A JP2019559378A JP2019559378A JP2020518584A JP 2020518584 A JP2020518584 A JP 2020518584A JP 2019559378 A JP2019559378 A JP 2019559378A JP 2019559378 A JP2019559378 A JP 2019559378A JP 2020518584 A JP2020518584 A JP 2020518584A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding
rnf43
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019559378A
Other languages
English (en)
Japanese (ja)
Inventor
真由美 星野
真由美 星野
由美子 川合
由美子 川合
敬弘 石黒
敬弘 石黒
智志 相田
智志 相田
慶直 類家
慶直 類家
シュー ウェン サマンサ ホー
シュー ウェン サマンサ ホー
シュウェット テン リー
シュウェット テン リー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JP2020518584A publication Critical patent/JP2020518584A/ja
Priority to JP2023105929A priority Critical patent/JP2023123726A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019559378A 2017-05-02 2018-05-02 細胞傷害誘導治療剤 Pending JP2020518584A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023105929A JP2023123726A (ja) 2017-05-02 2023-06-28 細胞傷害誘導治療剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017091955 2017-05-02
JP2017091955 2017-05-02
PCT/JP2018/017495 WO2018203567A1 (en) 2017-05-02 2018-05-02 Cytotoxicity-inducing therapeutic agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023105929A Division JP2023123726A (ja) 2017-05-02 2023-06-28 細胞傷害誘導治療剤

Publications (1)

Publication Number Publication Date
JP2020518584A true JP2020518584A (ja) 2020-06-25

Family

ID=64016153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019559378A Pending JP2020518584A (ja) 2017-05-02 2018-05-02 細胞傷害誘導治療剤
JP2023105929A Pending JP2023123726A (ja) 2017-05-02 2023-06-28 細胞傷害誘導治療剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023105929A Pending JP2023123726A (ja) 2017-05-02 2023-06-28 細胞傷害誘導治療剤

Country Status (4)

Country Link
US (2) US20200123256A1 (enExample)
EP (1) EP3619238A4 (enExample)
JP (2) JP2020518584A (enExample)
WO (1) WO2018203567A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024509695A (ja) * 2021-02-03 2024-03-05 ジェネンテック， インコーポレイテッド 多重特異性結合タンパク質分解プラットフォームおよび使用方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2647707T (lt) * 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
JP7219005B2 (ja) 2015-12-28 2023-02-07 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
WO2018140821A1 (en) 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
AU2019301633A1 (en) 2018-07-09 2021-01-28 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses
WO2021207613A1 (en) * 2020-04-10 2021-10-14 2Seventy Bio, Inc. Frb antibodies
CN112175080B (zh) * 2020-10-22 2021-05-25 优睿赛思(武汉)生物科技有限公司 抗人白介素-6高亲和力兔单克隆抗体及应用
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド 肝臓特異的Ｗｎｔシグナル増強分子およびその使用
CN119604527A (zh) * 2022-02-28 2025-03-11 安得泰医药有限公司 抗程序性死亡配体1（pd-l1）抗体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095392A1 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Anti-cd3 antibodies and methods of use
WO2015164392A2 (en) * 2014-04-21 2015-10-29 Stemcentrx, Inc. Novel antii-rnf43 antibodies and methods of use
WO2016179003A1 (en) * 2015-05-01 2016-11-10 Genentech, Inc. Masked anti-cd3 antibodies and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095392A1 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Anti-cd3 antibodies and methods of use
WO2015164392A2 (en) * 2014-04-21 2015-10-29 Stemcentrx, Inc. Novel antii-rnf43 antibodies and methods of use
WO2016179003A1 (en) * 2015-05-01 2016-11-10 Genentech, Inc. Masked anti-cd3 antibodies and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024509695A (ja) * 2021-02-03 2024-03-05 ジェネンテック， インコーポレイテッド 多重特異性結合タンパク質分解プラットフォームおよび使用方法

Also Published As

Publication number Publication date
JP2023123726A (ja) 2023-09-05
EP3619238A4 (en) 2021-02-24
EP3619238A1 (en) 2020-03-11
WO2018203567A1 (en) 2018-11-08
US20200123256A1 (en) 2020-04-23
US20240239890A1 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
US20240239890A1 (en) Cytotoxicity-inducing therapeutic agent
JP7273904B2 (ja) 液性免疫応答の増強方法
JP7054402B2 (ja) 細胞傷害誘導治療剤
JP6773929B2 (ja) 細胞傷害誘導治療剤
JP7314146B2 (ja) 細胞傷害誘導治療剤
KR101834708B1 (ko) 암의 치료에 이용하기 위한 세포상해 유도 치료제
KR102568808B1 (ko) 면역활성화 항원 결합 분자
US20180171017A1 (en) Combined use of immune activators
US20210054076A1 (en) Cytotoxicity-inducing therapeutic agent
JP6175590B1 (ja) 癌の治療に用いるための細胞傷害誘導治療剤
JP2020075879A (ja) 抗ｒｎｆ４３抗原結合分子及びその使用
HK40056927A (en) Cytotoxicity-inducing therapeutic agent
HK1258783A1 (en) Cell injury inducing therapeutic drug for use in cancer therapy
HK1258783B (zh) 用於癌症治疗的诱导细胞损伤的治疗药物
HK1234781A1 (en) Cytotoxicity-inducing therapeutic agent
HK1234781B (zh) 诱导细胞毒性的治疗剂
NZ730615B2 (en) Cytotoxicity-inducing therapeutic agent

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250304